Merck acquisition of OncoImmune : Pharma giant Merck has signed an all-cash deal worth $425 million to acquire OncoImmune to gain access to the latter’s investigational Covid-19 drug – CD24Fc. Based in Maryland, OncoImmune is a clinical-stage biopharma company, that is focused on the discovery and development of therapies for cancer and autoimmune disease. As […]
Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash deal, in a move to strengthen its oncology pipeline. VelosBio is engaged in developing cancer therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The company’s lead investigational candidate […]
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two new strategic oncology collaborations. The two major pharma companies will develop and commercialize Seattle Genetics’ ladiratuzumab vedotin across the world. Ladiratuzumab vedotin is an investigational antibody-drug conjugate (ADC) that targets LIV-1, which is presently in phase 2 […]
Merck acquisition of Themis Bioscience : Merck has signed a deal to acquire Themis Bioscience, an Austrian vaccine developer for an undisclosed price with an objective to gain access to the latter’s coronavirus vaccine candidate. Themis Bioscience by leveraging its measles virus vector platform has developed a pipeline of vaccine candidates and immune-modulatory therapies. Recently, […]
Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share or about $2.7 billion as per the latest pharma acquisition news. The pharma giant announced the deal in December 2019 in a move to further diversify its oncology pipeline with the Massachusetts-based ArQule focused on developing kinase […]
Merck acquisition of Peloton : Pharma giant Merck is set to acquire US biopharma company Peloton Therapeutics in a deal worth up to $2.2 billion, according to pharma acquisition news. Based in Texas, Peloton Therapeutics is a clinical-stage company engaged in the development of small molecule therapeutics that target hypoxia-inducible factor-2α (HIF-2α) for the treatment […]
Merck has achieved a significant milestone by obtaining approval from the European Commission (EC) for its cancer immunotherapy, Keytruda (pembrolizumab), to be used in combination with Eli Lilly’s chemotherapy drug pemetrexed (ALIMTA) and platinum chemotherapy. This approval specifically targets the first-line treatment of metastatic nonsquamous non-small cell lung cancer (NSCLC) in adults who do not […]